There is much interest in the use of extracellular vesicles (EVs) as a subcellular therapy for regenerative medicine and drug delivery. Blood-borne platelets represent a source of therapeutic EVs that is so far largely unexplored. Advantages of platelets as a cellular source of EVs include their established clinical value, regulated collection procedures, availability in a concentrated form, propensity to generate EVs, and unique composition and tissue-targeting capacity. This review analyzes the unique potential of platelet-derived (p-) EVs as therapeutic modalities and presents their inherent translational advantages for hemostasis, for regenerative medicine, and as drug-delivery vehicles.

人们对使用细胞外囊泡 (EV) 作为再生医学和药物递送的亚细胞疗法很感兴趣。血源性血小板代表了治疗性 EVs 的来源，但迄今为止在很大程度上尚未得到探索。血小板作为 EV 的细胞来源的优势包括其已确定的临床价值、受监管的收集程序、浓缩形式的可用性、产生 EV 的倾向以及独特的成分和组织靶向能力。本综述分析了血小板衍生 (p-) EV 作为治疗方式的独特潜力，并展示了它们在止血、再生医学和作为药物输送载体方面的固有转化优势。